Bioplatinum Technologies LLC is pleased to announce the award of an STTR proposal 1R41CA287830-01A1 “Precision medicine for pancreatic cancer. Biomarker-guided drug delivery of platinum to tumors”

Public Health Relevance Statement. Here, we will test the central hypothesis that platinum drugs devised to target and penetrate the tumor glycocalyx barrier will achieve enhanced levels of drug uptake in models of pancreatic cancer translating into enhanced clinical efficacy. These findings will address the two critical unmet needs in the treatment of pancreatic cancer to find 1) therapeutics to effectively treat drug resistant disease and 2) predictive biomarkers to identify which patients will benefit most from the available therapies.